Smart Biomolecules, Inc. — Department of Health and Human Services STTR Phase I: NIAID
Smart Biomolecules, Inc. — STTR Phase I award from Department of Health and Human Services.
- Amount
- $225,000
- Agency
- Department of Health and Human Services · National Institutes of Health
- Program / Phase
- STTR · Phase I
- Topic
- NIAID
- Solicitation
- PA14-072
- NAICS
- —
- Place of performance
- FL
- Period
- 2015-08-07 → 2016-07-31
Description
DESCRIPTION provided by applicant In spite of all the advances in molecular medicine malaria still afflicts about million people worldwide and half of the world population is at rik The disease causes nearly million deaths each year mostly children Unfortunately the prospects for control of malaria by chemotherapy have been seriously compromised by the emergence of resistance to all available drugs Most of the current malaria therapeutics was developed more than years ago and many are derived from older chemotypes Given the severity of the global malaria situation it is extremely urgent to identify potent and safe chemicl entities with antimalarial activity that are structurally distinct from existing antimalarials The proposed phase I STTR research project which is a partnership between Smart Biomolecules Inc and the University of Central Florida seeks to discover and further develop novel antimalarial scaffolds through screening of the Torrey Pines Institute for Molecular Studies TPIMS proprietary high density combinatorial libraries containing of over million compounds Because the TPIMS compound libraries occupy underrepresented areas of chemical space and have large degree of molecular complexity we hypothesize that the proposed studies will identify novel pharmacophores thus contributing significantly to the malaria elimination campaign Arrangement of the libraries in the scaffold ranking and positional scanning formats will enable us to screen the entire collection very rapidly Our preliminary work has identified novel scaffolds from the piperazine tethered thiazole library to possess potent and selective anti plasmodial activity To accomplish our objective to identify leads for malaria therapy from this series of compounds we propose to a Deconvolute the piperazine tethered thiazole library to identify selective lead compounds and b Determine development stage specific action and resistance potential Evaluate the in vivo efficacy of piperazine tethered thiazole lead compounds PUBLIC HEALTH RELEVANCE Malaria is one of the major tropical diseases afflicting over million and killing about million individuals annually Majority of the current treatments fo malaria are becoming ineffective because of emergence of drug resistance parasites Therefore it is urgent to develop new malaria therapeutics to mitigate this serious problem The proposed phase I STTR research seeks to discover drug leads based on piperazine tethered thiazole scaffold The proposal is timely as it will establish novel therapeutic interventions for malaria